ESMO Live Update | Dr. Girard Analyzes PAPILLON: Opening New Doors for First-Line Treatment of EGFR Exon 20 Insertion Mutant Advanced NSCLC
Based on the results of the PAPILLON trial, presented at the 2023 ESMO Congress, a dual-specificity EGFR/MET monoclonal antibody has the potential to become a standard of care for EGFR exon 20 insertion mutant advanced or metastatic non-small cell lung cancer (NSCLC), although toxicity management must be approached with caution (Abstract LBA5). Dr. Nicolas Girard, the lead author of the study and a researcher at the Curie-Montsouris Thoracic Institute, discussed the implications of these findings for clinical practice in an interview with Oncology Insight conducted during the conference.